Discover 2,163 paid clinical trials in Carlsbad, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 2,163
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
for
Breast Neoplasms
Location: Newport Beach CA, Cerritos CA, Los Angeles CA,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT06926868
Phase 2, Phase 3, Recruiting
First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671
for
Obesity
Location: Lake Forest CA, Webster TX, Dilworth MN
Sponsor: Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics
Sex: All
Age: 25 - 70+
Code: NCT07815678
Phase 1, Phase 2, Recruiting
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function
for
Hepatic Impairment, Healthy
Location: Lake Forest CA, Tampa FL, Orlando FL
Sponsor: Pfizer
Sex: All
Age: 18 - 70+
Code: NCT07269301
Phase 1, Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
for
Esophageal Squamous Cell Carcinoma
Location: Orange CA, Fullerton CA, Phoenix AZ, Fort Worth TX,
Sponsor: Daiichi Sankyo
Sex: All
Age: 18+
Code: NCT06644781
Phase 3, Recruiting
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
for
Renal Impairment, Healthy
Location: Lake Forest CA, Saint Paul MN, Tampa FL, Orlando FL
Sponsor: Pfizer
Sex: All
Age: 18 - 70+
Code: NCT07315360
Phase 1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy
Location: Irvine CA, Duarte CA, Aurora CO, Portland OR,
Sponsor: AstraZeneca
Sex: All
Age: 18 - 70+
Code: NCT05797168
Phase 1, Phase 2, Recruiting
Shield Post-Approval Study Protocol
for
Colo-rectal Cancer
Location: Anaheim CA, Palm Springs CA, Winnetka CA,
Sponsor: Guardant Health, Inc.
Sex: All
Age: 45 - 70+
Code: NCT06880055
Recruiting
Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis
for
Ulcerative Colitis (UC)
Location: Chula Vista CA, Nashville TN
Sponsor: Vanda Pharmaceuticals
Sex: All
Age: 18 - 70+
Code: NCT07686081
Phase 3, Recruiting
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
for
Atopic Dermatitis
Location: Newport Beach CA, Las Vegas NV, Phoenix AZ, Fremont CA,
Sponsor: Galderma R&D
Sex: All
Age: 12+
Code: NCT06988605
Recruiting
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
for
Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
Location: Chula Vista CA, Colorado Springs CO, San Antonio TX,
Sponsor: Takeda
Sex: All
Age: 18 - 70+
Code: NCT07646678
Phase 2, Phase 3, Recruiting
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
for
Hypertension, Uncontrolled Hypertension
Location: Chula Vista CA, Tempe AZ, Dublin CA, Walnut Creek CA,
Sponsor: Vanda Pharmaceuticals
Sex: All
Age: 18 - 65
Code: NCT07090161
Phase 2, Recruiting
Prospective, Open-label, Non-significant Risk, Multicenter Study Comparing the Polyp Detection of the Study Device to That of the Colonoscopy Reference
for
Colonic Polyps
Location: Chula Vista CA, Orange CA, Lancaster CA, Naperville IL,
Sponsor: Capso Vision, Inc.
Sex: All
Age: 45 - 70+
Code: NCT07089615
Recruiting
Wearable Device and Behavioral Support for Enhancing Arm Use After Stroke
for
Chronic Stroke Patients
Location: Irvine CA
Sponsor: University of California, Irvine
Sex: All
Age: 18 - 70+
Code: NCT07042152
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)